Study of PT0253 for advanced solid tumors with KRAS G12D mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer that has spread or cannot be removed by surgery.
- A lab test has shown that your cancer has a specific change called KRAS G12D.
- Your cancer can be measured on scans (like CT or MRI).
- You are able to do your normal daily activities (with some effort, but not bedridden).
- You agree to use birth control during the study and for 90 days after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.